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Objectives: The objective of this study was to evaluate the long-term efﬁcacy, safety, and tolerability of
paliperidone extended-release (pali ER), in Chinese patients with schizophrenia.
Methods: In this parallel-group, relapse prevention, phase-3 study (screening [14-day], pali ER open-label run-in
[8-week] and stabilization [6-week] phases, and double-blind (DB) treatment [variable duration], and open-label
extension phases [24-week]), 136/201 patients with schizophrenia were randomized (1:1) to pali ER (3–12mg)
or placebo during the DB phase.
Results: Final analysis showed that, out of 135 patients in ITT (DB) population, 71 (52.6%) had a relapse event, 45
(33.3%)were ongoing at the time the studywas stopped, and 19 (14.1%) discontinued from theDB phase. Time to
relapse (primary endpoint) favored pali ER (hazard ratio= 5.23 [95% CI: 2.96, 9.25], p b0.0001). Rate of relapses
(55/71 [77.5%] placebo; 16/64 [25%] pali ER) and secondary endpoints (change from baseline in Positive And
Negative Syndrome Scale [PANSS] and Clinical Global Impression — Severity Scores) were signiﬁcantly lower
(p b 0.001) in pali ER group vs placebo, in favor of pali ER. More psychiatric-related treatment-emergent adverse
events (TEAEs) occurred in placebo- (21.1%) than pali ER group (10.9%). Most common (N3%) TEAEs in placebo
group were insomnia and schizophrenia (8.5% each), while in pali ER groupwere aggression and akathisia (4.7%
each), and schizophrenia, tremor, nausea, amenorrhea, and salivary hypersecretion (3.1% each). All serious TEAEs
were psychiatric-related (schizophrenia, aggression, completed suicide, auditory hallucination, suicide attempt)
andmore frequent in placebo- (11.3%) versus pali ER group (3.1%). Death and tardive dyskinesia-related discon-
tinuation (n= 1 each) occurred in placebo group. Body weight increase from run-in baseline was greater in pali
ER group (mean increase: 3.90 kg) versus placebo (mean increase: 2.05 kg).
Conclusions: This study conﬁrms the ﬁndings from earlier pali ER global relapse-prevention studies and demon-
strates that pali ER treatment (3–12 mg) is efﬁcacious over the long-term and signiﬁcantly delays relapse in
Chinese patients with schizophrenia. No new safety signals were detected in this population.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).involuntary movement scale;
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. This is an open access article under1. Introduction
Schizophrenia accounts for 55% of all psychotic disorders in the adult
Chinese population (Li, 2011). Second generation antipsychotics (SGAs)
are preferred as the primary treatment option in patients with schizo-
phrenia, as they are effective in the treatment of both positive and neg-
ative symptoms (Csernansky et al., 2002; Kane et al., 2002; Lehman
et al., 2004; Schooler et al., 2005; Taylor, 2003) and associated with
fewer motor adverse effects. In China, the use of SGAs for the treatment
of schizophrenia has increased from53% in 1999 to 77% in 2008 and oral
antipsychotics like olanzapine, quetiapine and risperidone are widely
used (An et al., 2010).
Schizophrenia is a chronic condition requiring consistent, long-term
treatment; it is common for patients to discontinuemedication on their
own (Kramer et al., 2007). Non-adherence to oralmedications results inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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sion or even treatment failure (Emsley et al., 2008b). Thus, adherence
to long-term treatment of schizophrenia remains a major treatment
concern.
Paliperidone extended-release (pali ER), a SGA designed to deliver
paliperidone at a relatively constant rate over a 24-hour period, is
approved in the United States, European Union, and many other
countries for the treatment of schizophrenia in adults (Invega prod-
uct information, 2007). Pali ER is also approved in the United States
and EuropeanUnion asmono- and adjunctive therapy for the treatment
of schizoaffective disorder (Invega product information, 2007). In
completed clinical studies, pali ER 3 to 15 mg/day is efﬁcacious and
generally well-tolerated (Emsley et al., 2008a; Kane et al., 2007;
Kramer et al., 2010). Asians generally accounted for a very small
(≤5%) percentage of these study populations. It is well established
that race and ethnic differences can inﬂuence treatment response,
as well as the type and the extent of adverse events associated
with antipsychotic treatment (Banerjee, 2012; Bhugra and Bhui, 1999;
Coppola et al., 2012; Versola-Russo, 2006; Williams and Earl, 2007).
Consequently, studies conducted in populations composed primar-
ily of speciﬁc ethnic backgrounds or races are needed. The current
study was hence conducted to conﬁrm the efﬁcacy of pali ER in
delaying time to relapse and its overall safety in Chinese patients
with schizophrenia.
2. Methods
2.1. Patients
The study was conducted at 18 sites within the People's Republic
of China (from June 2011 to April 2013). Patients of either sex, aged
≥18 years, diagnosed with schizophrenia based on Diagnostic and
Statistical Manual of Mental Disorders, 4th version (DSM-IV-TR) for
at least 1 year before screening, and a Positive and Negative Syn-
drome Scale (PANSS) total score between 70 and 120 (inclusive), at
screening and baseline were eligible for enrollment.
Major exclusion criteria for the study included: drug dependence
(excluding nicotine and caffeine dependence) within 6 months before
screening according to DSM-IV, history of cardiovascular, respiratory,
neurologic, renal, hepatic, endocrine, or immunologic diseases, pres-
ence of circumstances that may increase the risk of the occurrence of
torsade de pointes or sudden death, heart rate b 50 bpm, presence of
congenital prolongation of the QT interval or demonstration of repeated
prolonged QTc Fridericia interval N 450 ms in N1 electrocardiogram
(ECG), neuroleptic malignant syndrome and hypersensitivity to risper-
idone, paliperidone, or their excipients. Patients treated with clozapine
for treatment refractory or treatment resistant schizophrenia, mono-
amine oxidase inhibitor antidepressants within 4 weeks before screen-
ing, depot antipsychotic drugs within 120 days, paliperidone palmitate
within 10 months or electroconvulsive therapy within 60 days before
screening, and pregnant and lactating women were all excluded from
the study.
The Independent Ethics Committee or Institutional Review Board
at each study site approved the protocol. The study was conducted in
accordance with the ethical principles that have their origin in the
Declaration of Helsinki, consistent Good Clinical Practices, and appli-
cable regulatory requirements. All participants provided written in-
formed consent.
2.2. Study design, randomization, and blinding
This phase 3, placebo-controlled, parallel-group study consisted of 5
phases (Fig. 1): screening phase of up to 14 days; 8-week open-label,
run-in (RI) phase; 6-week open-label stabilization (ST) phase; double-
blind (DB) treatment phase of variable length; and a 6-month open-label extension phase. Data from the open-label extension phase will
be reported separately.
During the 8-week RI phase, eligible patients received ﬂexibly-
dosed pali ER once daily in a dose range of 3 to 12 mg: an initial
dose of 6 mg was gradually increased by 3 mg/day after 5 days and
decreased as deemed necessary by the investigator based on
patient's tolerability. Patients were recommended to be hospitalized
for 8 days from the start of this phase and followed as outpatients
thereafter if the investigator judged them not to be of signiﬁcant
risk for suicidal or violent behavior and their Clinical Global Impres-
sion — Severity (CGI-S) score was 4 (moderately ill) or less. Only
those patients capable of maintaining a stable dose regimen in the
last week of this phase and with PANSS score b70, and prespeciﬁed
individual PANSS scores (P1 [delusions], P2 [conceptual disorganiza-
tion], P3 [hallucinatory behavior], P6 [suspiciousness/persecution],
P7 [hostility], and G8 [uncooperativeness]) ≤4 were eligible to
enter the ST phase during which they received the established ﬁxed
dose of pali ER.
Patients who completed the RI and ST phases of the study andmet
the following criteria, entered the DB phase: no changes in dose in ST
phase, no deliberate self-injury or violent behavior resulting in clin-
ically signiﬁcant injury to self or another person or property damage,
no psychiatric hospitalization (involuntary or voluntary admission
to a psychiatric hospital for decompensation of the patient's schizo-
phrenic symptoms, PANSS score b 70) and prespeciﬁed individual
PANSS scores (P1, P2, P3, P6, P7 and G8)≤4. Patients were randomized
1:1 to receive either pali ER (at the previously established dose) or
placebo via an online interactive web-based response system and/or
interactive voice response system.
2.3. Study medication
In the DB phase, pali ER or matching placebo tablets were
overencapsulated; pali ER tablets were provided at once daily dose of
3, 6, 9 or 12 mg. These doses were derived from 3 or 6 mg tablets
with 1 to 2 tablets depending on dose. In the RI and ST phases, pali ER
tablets without overencapsulation were provided.
2.4. Efﬁcacy
The primary efﬁcacy endpoint was the time-to-ﬁrst relapse during
the DB phase. Relapse was deﬁned as one or more of the following:
(1) hospitalization for symptoms of schizophrenia (involuntary or
voluntary admission), (2) deliberate self-injury or violent behavior,
or suicidal or homicidal ideation that was clinically signiﬁcant, (3) 25%
increase in PANSS total score for patientswho scored N40 at randomiza-
tion, or a 10-point increase for patients who scored ≤40 at randomiza-
tion for two consecutive assessments (within 1 week), and (4) increase
in prespeciﬁed individual PANSS items scores (P1, P2, P3, P6, P7 andG8)
to ≥5 for patients whose score was ≤3 at randomization, or to ≥6 for
patients whose score was 4 at randomization for two consecutive as-
sessments (within 1 week). Secondary efﬁcacy endpoints included
change from double-blind baseline to endpoint in PANSS total score,
CGI-S and Personal and Social Performance Scale (PSP).
2.5. Safety
Safety assessments included extrapyramidal symptom (EPS) rating
scales (Abnormal InvoluntaryMovement Scale [AIMS], Barnes Akathisia
Rating Scale [BARS], the Simpson–Angus Rating Scale [SAS]), treatment-
emergent adverse events (TEAEs), clinical laboratory tests, 12-lead elec-
trocardiograms, vital signs measurement and physical examination
ﬁndings.
The Columbia Suicide Severity Rating Scale (C-SSRS) was admin-
istered to assess for suicidal ideation and behavior.
Fig. 1. Study ﬂow and patient disposition.
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2.6.1. Sample size determination
A total of 360 patients (180 per group) were planned to be enrolled
in the RI phase assuming that 50% of patients would drop out from
study. This was expected to provide at least 86 relapse events and to
provide the study with 90% power, at the 2-sided signiﬁcance level of
0.05. The median time to relapse was assumed as 11.6 months for
placebo and 24.1 months for pali ER (relative risk = 0.48). The Wang
and Tsiatis power boundary with shape parameter 0.15 was used
for sequential monitoring (Wang and Tsiatis, 1987). An interim anal-
ysis using an Independent Data Monitoring Committee (IDMC) was
pre-planned to be performed at a signiﬁcance level of 0.011 when
exactly 43 events were obtained. If the result of the interim analysis
was signiﬁcant, the DB phase had to be terminated and pali ER be de-
clared superior to placebo in delaying time to relapse. Otherwise, the
DB phase was to be continued until a total of 86 events were obtain-
ed, and a ﬁnal analysis be performed at a two-sided signiﬁcance level
of 0.045.2.6.2. Primary endpoint analysis
The time to relapse was determined as the time from randomiza-
tion to the ﬁrst relapse event in the DB phase. All patients who did
not have a relapse of symptoms (who withdrew without relapse,who was symptomatically stable without relapse when study was
terminated or who died before relapse) were treated as censored ob-
servations and time to censoring was determined as the time from
randomization to last dose in the DB phase. Kaplan–Meier method
was used to assess the primary efﬁcacy variable (time-to-relapse),
and the log-rank test (two-sided) was used to compare treatment
differences.
2.6.3. Secondary endpoint analyses
All secondary efﬁcacy analyses were performed at the 0.05 level
(two-sided) across treatment groupswith no adjustments formultiplic-
ity, using the last observation carried forward (LOCF) approach. Using
an analysis of covariance (ANCOVA) model with treatment and study
site, and double-blind baseline PANSS total score as a covariate, the
least squares means, p-values, 95% CIs were compared between the
pali ER- versus placebo-treated patients.
2.6.4. Exploratory analyses
Cox proportional hazard models (including treatment and one
covariate at a time) were used to estimate the hazards ratio (HR)
and its 95% conﬁdence interval (CI), and impact of various factors
(age [18–25, 26 to 50, 50 to 65, N65 years], sex, BMI [normal b 25,
overweight ≥ 25 to b30, obese ≥ 30 kg/m2], prior hospitalization
for psychosis at screening visit, duration of illness at screening visit
[≤3 years, N3 years]) upon time-to-relapse results.
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Efﬁcacy and safety analyses for the RI/ST phases used the all treated
analysis set, which included all patients who received at least one dose
of pali ER. All efﬁcacy analyses in the DB phase used the intent-to-treat
(ITT) analysis set, which included all randomized patients who received
at least one dose in the DB phase. Safety analysis set for the DB phase
was the same as the ITT analysis set.3. Results
3.1. Patient disposition
Of the 201 patients enrolled in the RI phase, 161 entered the stabili-
zation phase, of which, 136 (68%) patients were randomized to the DB
phase (71, placebo; 65, pali ER) (Fig. 1). One patient in the pali ER
group was randomized but did not receive any dose in DB phase, and
hence was not included in the ITT analysis set. The demographic and
baseline characteristics of the 135 patients in the ITT population were
generally similar (Table 1). Patients were predominantly women
(59%); mean age was 31.7 years (range: 18 to 61 years). A total of
153 (76%) patients received 1 or more psychotropic drugs before they
entered the study. The most commonly used classes of psychotropic
medications were the atypical antipsychotics (50%) and benzodiaze-
pines (40%). Overall, 17% of patients were using anti-EPS medications
before entering the RI phase. The most common (N10%) concomitant
psychotropic medications used during the RI and ST phases were ben-
zodiazepines (n = 55, 27%) which included lorazepam (n = 36, 18%)
and clonazepam (n = 14, 7%). During the DB phase of the study, 7% of
patients (10/135) received benzodiazepines with a higher percentage
of patients in placebo than in pali ER group (11% vs. 3%); the most com-
monwas lorazepam(4%). On the other hand, 69 patients (51%) received
concomitant psychotropic medications other than benzodiazepines.
Trihexyphenidyl (total: n = 57 [42%]; pali ER: n = 31 [48%]; placebo:
n = 26 [37%]) and propranolol (total: n = 14, 10%, pali ER: n = 7
[11%]; placebo: n = 7 [10%]) were the most commonly received con-
comitant psychotropic medications other than benzodiazepines, with
a higher percentage of patients in the pali ER group compared with pla-
cebo group on EPS medications (48% vs 38%).
Nineteen (14%) of the 135 patients in ITT population discontinued
from DB phase while 116 (86%) completed the study (i.e. relapsed or
remained relapse-free up to 9 Nov 2012). More patients in the pali ERTable 1
Demographic and baseline characteristics (Intent-to-Treat DB analysis set).a
Sex, n (%)
Men
Subpopulation, n (%)
Chinese (Han)
Other
Age in years, mean (SD)
Age category, n (%)
18–25 years
26–50 years
51–65 years
Run-in baseline BMI (kg/m2), mean (SD)
Previous hospitalization for psychosis, n (%)
Duration (days) of hospitalization for psychosis prior to run-in phase, mean (SD)
DB baseline PANSS total, mean (SD)
DB baseline CGI-S category, n (%)
Very Mild
Mild
Moderate
Marked
DB baseline PSP, mean (SD)
a 1 patient was randomized but did not receive any studymedication duringDB phase, andw
dard deviation; CGI-S: Clinical Global Impression — Severity; PANSS: Positive and Negative Syngroup (n = 14, 22%) withdrew from DB phase compared with the pla-
cebo group (n=5, 7%), with withdrawal of consent (n= 9, 14%) as the
most frequently reported reason for discontinuation from the study
(Fig. 1).
3.2. Treatment exposure
The mean duration of exposure to study drug in the RI phase was
53.2 days and patients received amean dose (mean ofmeandose for in-
dividual patients) of 8.51 mg/day. During the RI phase, the mode
dose of pali ER (the dose taken most frequently) was 9.0 mg/day
by 38% of patients. During the ST phase, the mode daily doses of
6 mg, 9 mg, and 12 mg were received by 20%, 41%, and 35% of the pa-
tients, respectively. Only 4% of patients received the mode dose of
3 mg during the ST phase. The mean mode dose received in the RI
phase was 9 mg (median duration of exposure: 56 days) and in the ST
phase was 9.2 mg (median duration of exposure: 42 days). During the
DB phase, the mode daily pali ER dose taken was 9 mg by 42%, 12 mg
by 38%, and 6 mg by 19% patients. The mean (of mean dose for individ-
ual patients) dose and meanmode dose received by patients in the pali
ER group was 9.5 mg/day each. Median duration of exposure in the DB
phase was 36 days (placebo) and 102 days (pali ER). Mean duration of
the study (including the RI/ST and DB phases but excluding the open-
label extension phase) was 153 days.
3.3. Efﬁcacy
3.3.1. Primary efﬁcacy
The interim efﬁcacy analysis performed at the time of the 61st re-
lapse event during the DB phase demonstrated a signiﬁcant differ-
ence in time to relapse between the 2 treatment groups, in favor of
pali ER compared with placebo (Chi-squared test statistic =
35.611, df = 1, p b 0.0001): Out of the 124 patients included in the
interim ITT analysis, 75.4% (49/65) in the placebo group and 20.3%
(12/59) in pali ER group experienced a relapse event. This difference
exceeded the threshold for signiﬁcance (p b 0.0216), resulting in the
IDMC recommendation to stop the study early. Based on Kaplan–
Meier estimates, the 25% quantile of time to relapse (estimated time
point at which 25% of patients have experienced a relapse event) was
10 days in the placebo group and 111 days in the pali ER group. Theme-
dian time to relapse (the estimated time point where 50% patientsPlacebo
(n = 71)
Paliperidone ER
(n = 64)
Overall
(N = 135)
30 (42) 25 (39) 55 (41)
69 (97) 63 (98) 132 (98)
2 (3) 1 (2) 3 (2)
32.3 (12.17) 31.1 (9.36) 31.7 (10.90)
27 (38) 25 (39) 52 (39)
36 (51) 37 (58) 73 (54)
8 (11) 2 (3) 10 (7)
23.37 (4.33) 23.32 (4.02) 23.35 (4.17)
32 (45) 33 (52) 65 (48)
81 (99.41) 89.2 (93.85) 85.2 (95.96)
51.5 (9.50) 53.4 (9.71) 52.4 (9.61)
22 (31) 17 (27) 39 (29)
38 (54) 27 (42) 65 (48)
10 (14) 16 (25) 26 (19)
1 (1) 2 (3) 3 (2)
69.9 (9.37) 69.3 (11.17) 69.6 (10.23)
as not included in Intent-to-Treat (DB phase) analysis set. BMI: bodymass index; SD: stan-
drome Scale; PSP: Personal and Social Performance.
Fig. 2. Kaplan–Meier plot of time to relapse (Intent-to-Treat double-blind analysis seta).
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timewas not estimable in the pali ER group because less than 50% of pa-
tients experienced a relapse event.
Final analysis results (n = 135) were conﬁrmatory; there was a
signiﬁcant difference (Chi-squared test statistic = 39.443, df = 1,
p b 0.0001) between the two treatment groups in the time to relapse
in favor of pali ER (Fig. 2). More patients in the placebo group (n =
55, 77.5%) experienced relapse compared with those in pali ER
group (n = 16, 25%) (Table 2). Based on Kaplan–Meier estimates,Table 2
Time to relapse during the double-blind phase and frequency distribution of relapse types (Int
Interim analysis
Placebo
(n = 65)
Paliperidone ER
(n = 59)
Total no. of patients with relapse, n (%) 49 (75.4) 12 (20.3)
25% quantile (95% CI) 10.0 (8.0; 22.0) 111.0 (23.0; NA)
75% quantile (95% CI) 98.0 (77.0; 141.0) (NA; NA)
P-valueb
Reasons for relapse, n (%)
Psychiatric hospitalization 4 (6) 0
Psychiatric hospitalization 4 (6) 0
PANSSc 46 (71) 11 (19)
10 point increase in total PANSS score 3 (5) 3 (5)
Increase of 25% in total PANSS score 43 (66) 8 (14)
Deliberate self-injury, violent behavior 3 (5) 1 (2)
Deliberate self-injury 1 (2) 1 (2)
Violent behavior 3 (5) 1 (2)
Suicidal or homicidal ideationd 2 (3) 1 (2)
Homicidal ideation 1 (2) 0
Suicidal ideation 1 (2) 1 (2)
Suicide attempt 1 (2) 1 (2)
PANSS items (P1, P2, P3, P6, P7, G8)a 19 (29) 1 (2)
Score ≥5 for 2 days 16 (25) 1 (2)
Score ≥6 for 2 days 3 (5) 0
a 1 patient was randomized but did not receive any study medication during DB phase, and
b Log rank test.
c Regression analysis of survival data based on Cox proportional hazards model with treatm
d Based on two consecutive assessments performed within one week.the 25% quantile of time to relapse was 15 days in the placebo
group and 111 days in the pali ER group. The instantaneous risk
(hazard) of relapse of schizophrenia symptoms was 5.23 (95% CI:
2.96, 9.25) times higher for a patient switching to placebo than for
a patient continuing to receive pali ER. The most common reasons
for relapse included increase in the PANSS total score value and
changes (worsening) in PANSS items scores (Table 2). Most patients
in both pali ER and placebo groups were clinically managed without
the need for psychiatric hospitalization. Patients who experiencedent-to-Treat DB analysis set).a
Final analysis
Overall
(N = 124)
Placebo
(n = 71)
Paliperidone ER
(n = 64)
Overall
(N = 135)
61 (49.2) 55 (77.5) 16 (25.0) 71 (52.6)
22.0 (15.0; 29.0) 15.0 (8.0; 24.0) 111.0 (26.0; NA) 22.0 (17.0; 29.0)
(NA; NA) 108.0 (77.0; 141.0) (NA; NA) (NA; NA)
b0.0001 b0.0001
4 (3) 4 (6) 1 (2) 5 (4)
4 (3) 4 (6) 1 (2) 5 (4)
57 (46) 52 (73) 15 (23) 67 (50)
6 (5) 3 (4) 3 (5) 6 (4)
51 (41) 49 (69) 12 (19) 61 (45)
4 (3) 4 (6) 1 (2) 5 (4)
2 (2) 1 (1) 1 (2) 2 (1)
4 (3) 4 (6) 1 (2) 5 (4)
3 (2) 2 (3) 1 (2) 3 (2)
1 (1) 1 (2) 0 1 (1)
2 (2) 1 (2) 1 (2) 2 (2)
2 (2) 1 (2) 1 (2) 2 (2)
20 (16) 22 (31) 1 (2) 23 (17)
17 (14) 19 (27) 1 (2) 20 (15)
3 (2) 3 (4) 0 3 (2)
was not included in Intent-to-Treat (DB phase) analysis set.
ent as a factor.
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were treated with pali ER.3.3.2. Secondary efﬁcacy
Schizophrenia symptoms improved from RI baseline to endpoint
(RI/ST). In the DB phase, mean (SD) total PANSS scores signiﬁcantly
worsened (compared with DB baseline) in placebo-treated patients
(n = 71) (16.9 [16.16]) while they remained relatively stable in the
pali ER-treated patients (n = 64) (2 [12.67]). Based on ANCOVA
modelwith treatment (placebo, pali ER) and center as factors, and base-
line value as a covariate, the least squares means difference of pali ER
minus placebo for change in PANSS total score from DB baseline to
DB end point was−14.3 (SE = 2.49) (F test = 32.83, df = [1, 115],
p b 0.001 [two-sided]), which showed a signiﬁcant difference be-
tween the two groups in favor of pali ER compared with placebo
(Fig. 3).
During the RI and ST phases, patients' PANSS subscale and factor
scores improved. In the DB phase, although the mean PANSS factor
scores worsened (compared with DB baseline) in both treatment
groups, the placebo group had a greater mean change (increase) at DB
endpoint than the pali ER group for all factor scores, except for
“disorganized thought”, which showed no change in the pali ER
group (Table 3).
The psychotic condition of patients improved on the CGI-S scale
during the RI and ST phases; only 34 (17.0%) out of 157 patients
had a CGI-S score of ≥5 at the end of the ST phase, while it was
78.1% at RI baseline. At the end of DB phase, more patients in pali
ER group (68.8%), as compared with the placebo group (31.0%),
had severity scores of ‘mild’, ‘very mild’, or ‘not ill’ in CGI-S scores,
which showed the bigger improvement of CGI-S scores in the pali
ER group. Based on the analysis results of ranks of CGI values using
ANCOVA with treatment (placebo, pali ER) and center as factors,
and baseline value as a covariate, pali ER was signiﬁcantly superior
to placebo on the rank of changes in CGI value from DB baseline toFig. 3. PANSS total score over time (run-in,DB end point (F test = 39.82, df = [1,115], p b 0.001 [two-sided])
(Table 3).
Mean (SD) PSP total scores improved from RI baseline (43.6 [13.96])
to RI/ST endpoint (64.3 [14.78]). The least squares mean difference
of pali ER minus placebo for change in PSP total score from DB baseline
to DB end point was 7.1 (SE = 2.34) (F test = 9.18, df = [1,115], p =
0.003 [two-sided]), which showed a signiﬁcant difference between
two groups in favor of pali ER compared with placebo (Table 3).3.4. Safety
Overall, 81.1% of the 201 patients experienced at least 1 TEAE dur-
ing the RI and ST phases; the most common TEAEs (≥10% patients)
included akathisia (25.9%), tremor (11.9%), and insomnia (10.4%).
During DB phase, more patients in placebo group (40.8% [n = 29/71])
experienced TEAEs compared with pali ER group (32.8% [n = 21/64]).
The most common (≥10% patients) TEAEs were related to psychiatric
disorders, which occurred in 21.1% placebo-treated patients and 10.9%
pali ER-treated patients in pali ER group (Table 4).
A total of 12 patients (6%) experienced TEAEs that resulted in pali ER
discontinuation during the RI and ST phases, of which 5 patients (2.5%)
discontinued due to TEAEs related to psychiatric disorders (one patient
had restlessness, irritability, synesthetic hallucination and anxiety, one
patient each had restlessness, depressive symptom, psychotic disorder,
and suicidal ideation). Two patients discontinued the study due to
akathisia. All other TEAEs leading to study discontinuation (epilepsy,
nausea, constipation, amenorrhea, QT prolongation) were reported in 1
patient each. One patient of the placebo group discontinued treatment
in DB phase due to tardive dyskinesia. No deaths were reported during
the RI and ST phases, although one incidence of suicidal death (in
placebo group) was reported during the DB phase. Serious TEAEs
were reported in 2 patients (1%) during the RI and ST phases: psychotic
disorder and schizophrenia (each reported in 1 patient; 0.5%). During
the DB phase, serious TEAEs were reported more frequently in placebostabilization and double-blind phases).
Table 3
Change in secondary efﬁcacy measures from double-blind baseline to end of the double-
blind phase (Intent-to-Treat DB analysis set).a
Placebo
(n = 71)
Paliperidone ER
(n = 64)
PANSS total score, mean (SD)
Baseline 51.5 (9.50) 53.4 (9.71)
Change from baseline 16.9 (16.16) 2 (12.67)⁎
PANSS subscale scores, mean (SD)
Positive subscale
Baseline 10.5 (3.28) 10.6 (3.13)
Change from baseline 6.1 (5.83) 1.0 (4.26)
Negative subscale
Baseline 15.3 (4.03) 15.9 (4.43)
Change from baseline 2.3 (4.57) 0.3 (3.97)
General psychopathology
Baseline 25.6 (4.96) 26.8 (5.27)
Change from baseline 8.5 (8.57) 0.7 (7.22)
PANSS factor scores, mean (SD)
Positive symptoms
Baseline 14.2 (3.77) 14.5 (3.58)
Change from baseline 5.6 (5.45) 0.5 (4.88)
Negative symptoms
Baseline 14.7 (4.14) 15.0 (4.19)
Change from baseline 2.4 (5.15) 0.3 (4.26)
Disorganized thoughts
Baseline 11.8 (2.91) 12.4 (3.39)
Change from baseline 3.3 (4.07) 0.0 (3.03)
Uncontrolled hostility/excitement
Baseline 5.2 (1.93) 5.4 (2.14)
Change from baseline 3.8 (4.07) 0.6 (3.01)
Anxiety/depression
Baseline 5.6 (2.20) 6.1 (2.51)
Change from baseline 1.8 (3.32) 0.5 (3.03)
CGI-S score, mean (SD)
Baseline 2.9 (0.70) 3.0 (0.88)
Change from baseline 1.1 (1.11) 0.1 (0.91)#
PSP score, mean (SD)
Baseline 69.9 (9.37) 69.3 (11.17)
Change from baseline −10.7 (14.99) −2.9 (12.87)⁎⁎
SD: standard deviation; CGI-S: Clinical Global Impression— Severity; PANSS: Positive and
Negative Syndrome Scale; PSP: Personal and Social Performance.
# p b 0.001.
⁎ p b 0.0001.
⁎⁎ p b 0.003.
a 1 patient was randomized but did not receive any study medication during DB phase,
and was not included in Intent-to-Treat (DB phase) analysis set.
Table 4
Treatment-emergent adverse events in at least 2% of patients in either treatment group
(Intent-to-Treat DB analysis set).a
Placebo (n = 71)
n (%)
Pali ER (n = 64)
n (%)
Total number of patients with TEAEs 29 (41) 21 (33)
Schizophrenia 6 (9) 2 (3)
Insomnia 6 (9) 1 (2)
Aggression 2 (3) 3 (5)
Akathisia 0 3 (5)
Nausea 1 (1) 2 (3)
Tremor 0 2 (3)
Salivary hypersecretion 0 2 (3)
Amenorrhea 0 2 (3)
Agitation 2 (3) 0
Weight decreased 2 (3) 0
Nasopharyngitis 2 (3) 0
Oropharyngeal pain 2 (3) 0
a 1 patient was randomized but did not receive any study medication during DB phase,
and was not included in Intent-to-Treat (DB phase) analysis set. TEAEs: treatment-
emergent adverse events.
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psychiatric-related.
The most common EPS-related TEAEs reported in the RI and ST
phases were those grouped under hyperkinesia (31.3%), parkinsonism
(12.4%), and tremor (11.9%). In the DB phase, the incidence of EPS-
related TEAEs was higher in the pali ER group (9.4%; hyperkinesia
[6.3%] and tremor [3.1%]) compared with the placebo group (4.2%;
dyskinesia [2.8%] and parkinsonism [1.4%]): none of themwere serious.
This difference in EPS-related TEAEs is corroborated by the higher pro-
portion of patients in the pali ER group (48%) taking anti-EPS medica-
tions compared with placebo (38%) in the DB phase.
Four patients experienced prolactin-related TEAEs in the RI and
ST phase. Two patients experienced loss of libido, 1 experienced ga-
lactorrhea and 1 sexual dysfunction. Three women experienced ir-
regular menstruation and 2 women had amenorrhea; in DB phase,
1 woman (pali ER group) experienced galactorrhea, 2 women (pali
ER group) experienced amenorrhea and 1 woman of each group ex-
perienced irregular menstruation. During the RI and ST phases, pro-
lactin levels increased from baseline to the end of the RI phase in
both men and women; thereafter, they remained elevated at the
same level throughout the ST phase (mean [SD] change from RI base-
line to RI/ST endpoint: men: 25.6 [26.06] μg/L; women: 78.8 [73.39]μg/L). Mean prolactin levels of both men and women in the placebo
group decreased from DB baseline levels to levels within the reference
range at the end of the DB phase (change in mean [SD], men:−33.98
[15.99] μg/L; women:−90.33 [53.58] μg/L). On the other hand, in the
pali ER group, there was a gradual increase in mean prolactin levels
from the DB baseline during the ﬁrst 12 weeks of the DB phase (change
in mean [SD], men: 2.95 [8.31] μg/L; women: −12.98 [73.76] μg/L)
followed by a gradual decrease or stabilization for the remaining course
of the study (change in mean [SD], men:−5.59 [14.35] μg/L; women:
−24.40 [74.93] μg/L). Two patients experienced glucose-related
TEAEs during RI and ST phases while none did during the DB phase in
either treatment group.
TEAEs related to suicidality were reported for 1 patient (suicidal
ideation) during the RI and ST phases, and for 2 patients (suicide at-
tempt [pali ER group] and completed suicide [placebo], one each)
during the DB phase. A majority of patients (98%) had a maximum
C-SSRS score of 0 (no suicidal ideation), and 2% of patients had a score
of 1 (wish to be dead).
There were markedly abnormal increases in pulse rate, both
standing (14.2% patients) and supine (6.5% patients), with markedly
abnormal decreases in standing (8.2% patients) and supine systolic
blood pressure measurements (5.5% patients) in the RI and ST phases.
During the DB phase, more patients in the pali ER group had increased
standing pulse rate (pali ER 10% vs placebo 3%) and decreased supine
systolic blood pressure (pali ER 5% vs. placebo 0%). No cases of QTc
values exceeding 500 ms were reported at any time during the study.
Of the 200 patients with normal QTcLD values at baseline, 2 had
QTcLD values of N450 ms and 1 had QTcLD values of N480 ms during
the RI and ST phases. In the DBphase, QTcLD values shifted fromnormal
to N450 ms in 1/56 patients in the pali ER group only. There were no
instances of shifts from normal to N480 ms or N500 ms QTcLD inter-
val in either treatment group. The QTcLD values worsened more in
the placebo group than in the pali ER group with mean (SD) change
in QTcLD values from DB baseline to DB endpoint to be −6.4
(15.05) ms in the placebo group and −1.8 (16.70) ms in the pali
ER group. Body weight increase was reported as an AE in the open-
label RI and ST phases (6.5%) and DB phase (placebo 1.4% vs. pali
ER 1.6%). In the DB phase, body weight increases were more preva-
lent and greater in pali ER group (42%, mean [SD] increase: 3.90
[5.77] kg) versus placebo (30%, mean [SD] increase: 2.05 [4.85] kg).
4. Discussion
The current study demonstrated that ﬂexibly dosed pali ER treat-
ment (3–12 mg/day) signiﬁcantly delayed relapse in Chinese
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ommendations from the IDMC because the primary efﬁcacy end-
point (time to relapse) was met at the preplanned interim
analysis. The ﬁnal statistical analysis ﬁndings corroborated those of
the interim analysis. Additionally, results from an exploratory anal-
ysis further suggested that the efﬁcacy of pali ER with regard to time
to relapse of symptoms of schizophrenia was consistent regardless
of BMI, sex, age, prior hospitalization status, or duration of illness
(p b 0.0001 for all factors). Treatment with pali ER was associated with
an overall improvement in symptoms of schizophrenia as observed
with signiﬁcant reductions in PANSS total scores, individual PANSS
factor scores, CGI-SCH scores and increment in PSP scores at the
end of DB phase.
The study showed that 25% of pali ER-treated patients had re-
lapse; these results are consistent with a global long-term pali ER
study with a similar design wherein 22% of pali ER-treated patients
had relapse at ﬁnal analysis (Kramer et al., 2007). Our results are
also consistent with a recent meta-analysis of data of 6493 patients
with schizophrenia from 65 clinical trials, which demonstrated a re-
lapse in 25% of patients treated with antipsychotic drugs compared
with 69% of patients treated with placebo (Leucht et al., 2012). This
suggests pali ER's efﬁcacy in preventing relapse is similar in this Chi-
nese population as within a more diversiﬁed population.
Interestingly, relapse rates for placebo were higher in the current
study (77.5%) compared with the global long-term pali ER study (53%)
(Kramer et al., 2007). The difference in relapse rates in the placebo-
treated group in our study may be due higher dose received during
the run-in/stabilization phase in the global long-term pali ER study
(Kramer et al., 2007) compared with this study. Other possible reasons,
such as differing patient expectations about clinical trial treatments or
even standards of care between countries may also have contributed
to the difference.
Patients who continued on pali ER treatment from RI and ST
phases to DB phase had relatively stable PANSS scores over the 56
week period, compared with those who switched to placebo, show-
ing that symptom stability was maintained. Improvements were
also observed for all of the ﬁve symptomatic domains (PANSS
Marder factor scores) of schizophrenia: positive symptoms, negative
symptoms, depression/anxiety, uncontrolled hostility/excitement
and disorganized thoughts. Robust symptom improvement in pali-
ER-treated patients was further reﬂected in the improvements in
CGI-S scores. Categorical analysis of patients at baseline and DB end
point demonstrated improvement in the PSP scores by at least 1 cat-
egory in pali ER-treated patients compared with placebo. The results
of secondary efﬁcacy evaluations were thus alignedwith the primary
ﬁndings, supporting pali ER's efﬁcacy in this population, and were
also consistent with results from the global long term pali ER study
with similar design (Kramer et al., 2007). Overall, these ﬁndings also
corroborate data from other short- and long-term studies for pali
ER (Canuso et al., 2009; Davidson et al., 2007; Emsley et al., 2008a;
Kane et al., 2007; Kim et al., 2013; Kramer et al., 2007; Schmauss
et al., 2012).
Consistent with the global long-term pali ER studies, the results of
this study also suggest that continued beneﬁt is realized with ex-
tended treatment. Substantial improvement occurred in symptom
severity during the 14-week open-label RI and ST phases, and symp-
tom stability was achieved. Subsequently, within the ﬁrst 2 weeks of
the DB phase, there was a statistically signiﬁcant separation in the
number of efﬁcacy and quality-of-life measures between placebo-
and pali ER-treated patients. Pali ER-treated patients remained rela-
tively stable, whereas notable worsening of schizophrenia symp-
toms occurred in placebo-treated patients, thus indicating that pali
ER treatment maintained the signiﬁcant symptom control achieved
during the ST period.
The beneﬁcial effects following pali ER treatment may be a result
of supersensitivity psychosis; however, it is now shown that abruptor gradual withdrawal of prior treatment with antipsychotic drugs
in the placebo group does not change the relapse risk (Leucht et al.,
2012).
Safety ﬁndings in this population were consistent with the earlier
pali ER studies (Davidson et al., 2007; Emsley et al., 2008b; Kane et al.,
2007; Kramer et al., 2007, 2010). The incidence of TEAEs and discontin-
uation due to TEAEs was low in pali ER-treated patients compared with
placebo-treated patients. One case of suicidal ideation during the RI/ST
phase and 2 cases of suicide attempt during DB phase were reported
for the pali ER group.
Consistent with the known pharmacology of pali ER, there were in-
creases in plasma prolactin levels, which were more pronounced in
women than men. Similar to the earlier pali ER short- and long-term
studies, few prolactin-related TEAEs were reported and no worsening
of any other metabolic parameter was observed in this study (Kane
et al., 2007; Kramer et al., 2007).
The incidence of EPS-related TEAEs observed in this study is also
comparable to the global pali ER study (Kramer et al., 2007). None of
the EPS-related TEAEs in this trial were considered serious. EPS-
related TEAEs occurred more often in pali ER- than placebo-treated
patients, and more pali ER-treated patients required anti-EPS medi-
cations in the DB phase. This may also be attributed to the fact that
investigators usually tend to titrate upward from the starting dose of
6 mg/day and rarely reduce the dose even when efﬁcacy is achieved
in absence of any adverse event.
Glucose-related TEAEs were uncommon (1%) during the RI and ST;
there were no reports of glucose-related TEAEs during the DB phase
consistentwith the absence of clinicallymeaningful changes frombase-
line in mean glucose levels. The incidence of TEAEs of weight increased,
which represents patients with clinically signiﬁcant weight gain as
assessed by the investigators, was low in both the RI and ST phases
(6.5%), and DB phase (placebo 1.4% vs. pali ER 1.6%). The incidence of
treatment-emergent abnormalities in recorded ECG parameters (PR
and QRS intervals) was also low during the course of the study and
showed no clinically relevant differences between the two treatments
during the DB phase.
The study thus extended the ﬁndings from the earlier pali ER
relapse-prevention study and demonstrated that pali ER treatment
(3–12mg) was similarly efﬁcacious in preventing relapse and gener-
ally tolerable in Chinese patients with schizophrenia.
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